Glycomine

Glycomine's Mission for Rare Diseases
Glycomine is committed to developing therapeutics for serious rare diseases, the vast majority of which do not have any disease-modifying treatment options available. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. Even though the number of patients affected by any single disease may total several hundred or thousand, it is estimated the total number of people affected by all such diseases is more than 20 million in the U.S. alone.

Developing Substrate Replacement Therapies
Many of these diseases are driven by a genetic mutation that disrupts the production of an important protein. Glycomine’s therapeutic approach is to replace the protein or deliver a substrate or enzyme to bypass the deficiency in the protein. The company’s platform is then leveraged to ensure delivery to the clinically relevant cells and organ system. With this approach, Glycomine can establish a pipeline of therapeutic candidates to address a wide range of rare diseases.